Immunointervention with cyclosporin A in autoimmune neurological disorders.
Cyclosporin A has proven a remarkably effective compound in suppressing disease activity in a number of animal models of autoimmune neurological disorders. During the last decade a number of controlled clinical trials have been carried out in human neurological disorders which are considered to be immune-mediated. The results of those trials are reviewed.
Tindall
R S
RS
Department of Neurology, Southwestern Medical School, University of Texas, Dallas.
D000170:Acrodynia; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy; D001327:Autoimmune Diseases / Q000188:drug therapy*; D016572:Cyclosporine / Q000627:therapeutic use*; D003711:Demyelinating Diseases / Q000188:drug therapy; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy; D009157:Myasthenia Gravis / Q000188:drug therapy; D009220:Myositis / Q000188:drug therapy; D009422:Nervous System Diseases / Q000188:drug therapy*; D011129:Polyradiculoneuropathy / Q000188:drug therapy
D016572:Cyclosporine